Lumexa Imaging Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Q1 revenue grew 3% year-over-year to $253 million, with advanced modalities driving 7% volume growth and PET up 23%. Adjusted EBITDA was flat at $51.2 million, impacted by weather and seasonality, but guidance for 2026 remains strong with expected ramp in the second half.
-
Outpatient imaging growth is driven by advanced modalities, technology investments, and targeted de novo expansion. Strong commercial payer mix, transparent JV reporting, and AI-driven workflow improvements support financial performance and capacity growth.
-
Radiology is seeing rapid growth and consolidation, with advanced imaging driving revenue and margin expansion. The company leverages JV partnerships, de novo openings, and a strong commercial payer mix to fuel growth, while maintaining high patient satisfaction and transparent financial reporting.
-
Diagnostic imaging is a large, fast-growing, and fragmented market, with significant opportunities for expansion through de novo centers, joint ventures, and selective M&A. The business leverages technology and AI for efficiency, maintains high satisfaction rates, and targets consistent, capital-efficient growth.
Fiscal Year 2025
-
Delivered strong Q4 and full-year 2025 growth, driven by advanced imaging, new center openings, and technology adoption. 2026 guidance reaffirms revenue and EBITDA growth, with continued focus on advanced modalities, geographic expansion, and operational efficiency.